title: Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
abstract: All 178 HIV-infected individuals who had initiated tenofovir-emtricitabine-nevirapine (TDF/FTC/NVP) at our institution and were adherent to their medication were retrospectively examined. Only 22% were antiretroviral naive. After a median follow-up of 16 months, only five (2.8%) individuals (all with prior exposure to other antiretroviral regimens) experienced virological failure. In all instances, viral rebound occurred after 12 weeks of therapy. These results do not support an increased risk of early virological failure using TDF/FTC/NVP.
authors.affiliation: Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Labarga
authors.forename: Jose
authors.initials: J
authors.lastname: Medrano
authors.forename: Eduardo
authors.initials: E
authors.lastname: Seclen
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
authors.forename: Sonia
authors.initials: S
authors.lastname: Rodriguez-Novoa
authors.forename: Judit
authors.initials: J
authors.lastname: Morello
authors.forename: Carmen
authors.initials: C
authors.lastname: de Mendoza
authors.forename: Eugenia
authors.initials: E
authors.lastname: Vispo
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage*; D063065:Organophosphonates / Q000008:administration & dosage*; D012367:RNA, Viral; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D012367:RNA, Viral; D003841:Deoxycytidine; D019829:Nevirapine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine